JPRN-UMIN000017901已完成3 期
Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the Treatment of Male Stress Urinary Incontinence - Clinical Trial of ADRCs for the Treatment of Male Stress Urinary Incontinence (ADRESU study)
agoya University Hospital0 个研究点目标入组 45 人开始时间: 2015年7月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) Concurrent with any other types of urinary incontinence than stress urinary incontinence 2) History of urinary or reproductive surgery within 6 months prior to the consent 3) History of behavioral therapy or pharmacotherapy within 3 months prior to the consent 4) Concurrent with diabetes insipidus 5) History of radiotherapy in the lower urinary tract 6) History of ADRCs treatment for stress urinary incontinence 7) History of any type of cell therapy within 6 months prior to the consent 8) Participation in any other clinical trial within 3 months prior to the consent 9) Concurrent with lower urinary tract obstruction 10) Concurrent with urolithiasis, urinary tract infection or interstitial cystitis 11) History of recurrent urinary tract infection 12) History of malignant neoplasm within 5 years prior to the consent or a suspicion of it (Patients with a history of radical prostatectomy for localized prostate cancer without relapse/metastasis over 1 year may be enrolled) 13) Life expectancy of less than 1 year 14) Any other patients whom the trial investigator deemed ineligible to this study
研究者
相似试验
已完成
不适用
Single arm, Open Label, Multi-Centre study to evaluate the safety and performance of treatment of articular cartilage lesions located on the femoral condyle with GelrinCmusculoskeletaal stelsel (gewrichtskraakbeen)articular cartilage lesionarticular cartilage defectNL-OMON40108Regentis Biomaterials Ltd.10
进行中（未招募）
1 期
Study to assess the safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia or Homozygous Familial HypercholesterolemiaMedDRA version: 20.0Level: LLTClassification code 10057100Term: Homozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850HypercholesterolemiaEUCTR2015-002276-25-PTAmgen Inc163
进行中（未招募）
1 期
Study to assess the safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia or Homozygous Familial HypercholesterolemiaMedDRA version: 20.0Level: LLTClassification code 10057100Term: Homozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850HypercholesterolemiaEUCTR2015-002276-25-CZAmgen Inc115
已完成
不适用
Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)Hypercholesterolemia - HeFH10027424HoFHNL-OMON55627Amgen25
进行中（未招募）
1 期
Study to assess the safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia or Homozygous Familial HypercholesterolemiaHypercholesterolemiaEUCTR2015-002276-25-PLAmgen Inc115